Welcome to our dedicated page for ICON PLC news (Ticker: ICLR), a resource for investors and traders seeking the latest updates and insights on ICON PLC stock.
ICON plc (NASDAQ: ICLR) is a clinical research organisation headquartered in Dublin, Ireland, operating in the research and development in biotechnology industry. This news page focuses on company announcements and updates that relate to its clinical research activities, financial performance and corporate developments.
ICON’s news releases commonly cover quarterly financial results, including revenue, net income, adjusted EBITDA and related non‑GAAP measures. These updates often discuss business wins, book‑to‑bill ratios, cash generation and capital allocation decisions such as share repurchase activity, as reflected in the company’s second and third quarter 2025 results announcements.
Investors and industry observers can also find news about ICON’s participation in investor and healthcare conferences. The company regularly announces presentations at events such as global healthcare conferences and growth stock conferences, as well as the scheduling of earnings conference calls and webcasts. These items provide insight into how ICON communicates its strategy and performance to the market.
Corporate governance and leadership changes are another key news category. For example, ICON has announced a CEO transition, detailing succession planning and board decisions. The company also publishes the results of its annual general meeting, including shareholder votes on director elections, auditor ratification and share authorisations.
In addition, ICON highlights recognition of its clinical research capabilities, such as independent benchmarking reports that assess its performance in phase 1 clinical trials. News may also include updates on specific research programmes, such as vaccine study updates noted in its filings. For ongoing visibility into ICON plc’s operations, financial reporting and role as a clinical research organisation, this news feed aggregates company-issued information in one place.
ICON plc (NASDAQ: ICLR) announced the proposed acquisition of PRA Health Sciences, with the merger set to occur through ICON's wholly-owned subsidiary. The company plans to issue $500 million in Senior Secured Notes at 2.875% interest due 2026, replacing a previously planned offering of $1,515 million in 2028 notes due to an increase in credit facilities. The proceeds will fund the merger payment, refinance existing debt, and cover related expenses. The offering is expected to close on July 1, 2021, pending customary conditions.
ICON (NASDAQ: ICLR) announced the successful passing of all resolutions at its Extraordinary General Meeting held on June 15, 2021. Shareholders approved the issuance of ordinary shares related to the acquisition of PRA Health Sciences. The merger will see PRA operate as a subsidiary of ICON. Furthermore, PRA's stockholders also voted to adopt the Merger Agreement and approve executive compensation arrangements tied to the transaction. The merger is expected to close on July 1, 2021, pending any remaining conditions.
ICON plc (NASDAQ: ICLR) announced plans to acquire PRA Health Sciences via a merger, with a proposed offering of $2.015 billion in Senior Secured Notes. The funds will be used for cash consideration in the merger, refinancing existing debt, and covering related fees. The offering consists of $500 million of notes due 2026 and $1.515 billion due 2028, subject to market conditions. Successful completion of the merger depends on obtaining necessary approvals and satisfying closing conditions, which may present risks and uncertainties.
ICON plc (NASDAQ: ICLR), a leading global provider of outsourced drug and device development, announced key presentations at upcoming healthcare conferences. Mr. Brendan Brennan, CFO, will present at the Jefferies Virtual Healthcare Conference on June 1, 2021, at 08:00 AM ET. Dr. Steve Cutler, CEO, will present at the William Blair 41st Growth Stock Conference on June 2, 2021, at 11:40 AM ET. Live webcasts will be available on their Investor section. The company continues its strategic growth and service expansion in clinical development.
ICON plc (NASDAQ: ICLR), a leading global provider of outsourced drug and device development services, announced that CFO Brendan Brennan will present at two upcoming virtual healthcare conferences. The first presentation is scheduled for May 12, 2021, at the BofA Securities 2021 Virtual Healthcare Conference, followed by the UBS Virtual Global Healthcare Conference on May 24, 2021. For updates on these events, please check the Investor section of ICON's website. The company, headquartered in Dublin, employs approximately 16,070 staff across 89 locations globally.
ICON (NASDAQ: ICLR) reported strong financial results for Q1 2021 with revenue reaching $858 million, a 20% year-on-year increase. The company achieved record net business wins of $1.1 billion, up 27% year-on-year, and grew its backlog to $10 billion. Adjusted earnings per share rose 21% to $2.06. ICON has raised its full-year revenue guidance to $3.4 - $3.5 billion, reflecting a 21.6% - 25.1% increase year-on-year. The planned acquisition of PRA is set to close in July, enhancing ICON's market position.
ICON plc (NASDAQ: ICLR) recently announced that CFO Brendan Brennan will present at two significant events: the Barclays Global Healthcare Conference on March 10, 2021, at 08:00 am ET, and at the KeyBanc Capital Markets' Life Sciences & MedTech Investor Forum on March 24, 2021, at 11:30 am ET. The presentations will be accessible via live webcasts, with details available on the Investor section of ICON's website under 'Events.' ICON is a leading provider of outsourced drug and device development services, currently employing approximately 15,730 staff globally.
ICON plc (NASDAQ: ICLR) reported strong Q4 2020 results, with record net business wins of $1,080 million and a book-to-bill ratio of 1.42, increasing backlog to over $9.7 billion (up 13% YoY). Revenue grew by 5% to $760 million, and EPS rose to $1.90 (up 4%). For 2021, revenue guidance is set at $3,200 - $3,300 million, reflecting a 14% - 18% increase, with EPS guidance of $8.10 - $8.50 (24% - 30% increase). Despite the pandemic's challenges, ICON remains focused on safety and continues to manage over 120 COVID-19 trials. Full-year revenue declined slightly by 0.3% to $2,797 million.
ICON plc (NASDAQ: ICLR) has announced a definitive agreement to acquire PRA Health Sciences (NASDAQ: PRAH) for approximately $12 billion. The acquisition will involve $80 in cash and 0.4125 shares of ICON stock per PRA share, representing a 30% premium from PRA's closing price on February 23, 2021. The merger aims to enhance clinical trial execution and increase efficiency, delivering an estimated $150 million in cost synergies. The deal is expected to close in Q3 2021, subject to regulatory approvals.
Cytocom has submitted an IND application to the FDA for a Phase 2 clinical trial of CYTO-205, aimed at evaluating its efficacy against COVID-19. Preclinical studies indicate CYTO-205 may inhibit coronavirus strain 229E replication in lung cells. The trial, commencing in Q2 2021, targets high-risk adults with mild COVID-19 infection. Additionally, Cytocom partnered with ICON plc to manage the Phase 3 trial for CYTO-201, its lead candidate for Crohn's disease. The company emphasizes the need for effective COVID-19 therapies despite vaccine availability.
FAQ
What is the current stock price of ICON PLC (ICLR)?
What is the market cap of ICON PLC (ICLR)?
